Post-LASIK night vision drops from Opus Genetics cleared two Phase 3 trials, reducing halos and glare, with FDA Fast Track status already granted.
Opus Genetics reports 21% of LASIK patients hit key vision threshold in Phase 3 trials, with FDA approval decision pending 2026 data Nikshep Myle has been a dedicated writer for Gadget Review for over ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results